Joint Let­ter by the EC, EMA and HMA - Pro­vi­sion of Re­sults for Au­tho­rised Clin­i­cal Tri­als in Eu­draCT (June 2019)

ansparency in clinical trials is essential to protect health and foster innovation in medical research. The European Commission, the European Medicines Agency (EMA) and the heads of the regulatory authorities in the EU (HMA) have signed a public letter in which they remind all sponsors of clinical studies carried out in the EU to make the summaries of results of completed studies publicly available in the EU database for clinical studies.

The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, expressly supports this request and publishes the joint letter.

Updated: 07.01.2020